Abbott's Trading Volume Drops 39.91% to 6.72 Billion, Ranks 127th Despite FDA Approval and Stock Price Increase

On March 24, 2025, Abbott's trading volume reached 6.72 billion, a significant decrease of 39.91% compared to the previous day, ranking 127th in the day's stock market. Abbott's stock price increased by 0.69%.

Abbott has received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy (IVL) system. This approval allows Abbott to initiate a new clinical trial to evaluate the effectiveness of its IVL system in treating coronary artery disease. The trial, known as the TECTONIC trial, will enroll up to 335 participants across 47 U.S. sites. This development is expected to enhance Abbott's position in the medical device market, particularly in the treatment of cardiovascular diseases.

Abbott's recent FDA approvals and clinical trial initiations have garnered significant attention from investors. The company's focus on innovative medical devices and healthcare solutions, particularly in the areas of cardiovascular health and diabetes management, has positioned it as a leader in the medical technology sector. The successful outcomes of these trials could further solidify Abbott's market standing and potentially drive future growth.